**SDC 2.** Demographic Characteristics—All Enrolled Subjects

|  | Group 1  (n = 126) | Group 2  (n = 181) | Total  (N = 307) |
| --- | --- | --- | --- |
| Sex, n (%) |  |  |  |
| Male | 61 (48.4) | 107 (59.1) | 168 (54.7) |
| Female | 65 (51.6) | 74 (40.9) | 139 (45.3) |
| Race, n (%) |  |  |  |
| White | 96 (76.2) | 132 (72.9) | 228 (74.3) |
| Black or African-American | 18 (14.3) | 31 (17.1) | 49 (16.0) |
| Other | 7 (5.6) | 13 (7.2) | 20 (6.5) |
| Asian | 3 (2.4) | 2 (1.1) | 5 (1.6) |
| American Indian or Alaska Native | 1 (0.8) | 2 (1.1) | 3 (1.0) |
| Native Hawaiian or other Pacific Islander | 1 (0.8) | 1 (0.6) | 2 (0.7) |
| Age at enrollment\* | Months | Years | NA |
| Median | 17.2 | 3.0 | NA |
| Min, max | 15.1, 24.0 | 2.0, 5.0 | NA |
| Received a total of 3 doses of PCV7 prior to enrollment,\* n (%) | 37 (29.4) | 8 (4.4)† | 45 (14.7)† |
| Received a total of 4 doses of PCV7 prior to enrollment,\* n (%) | 89 (70.6) | 172 (95.0)† | 261 (85.0)† |

\*Data for age at enrollment, received 3 doses of PCV7 prior to enrollment, and received 4 doses of PCV7 prior to enrollment were for the evaluable immunogenicity population.

†The percentages do not total 100% because 1 enrolled subject who withdrew from the study before receiving the study vaccination was incorrectly listed as having received 0 doses of PCV7. The Case Report Form for this subject was not updated with the exact number of prior PCV7 doses.

NA indicates not available.